1. Home
  2. NVCR vs TRMK Comparison

NVCR vs TRMK Comparison

Compare NVCR & TRMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TRMK
  • Stock Information
  • Founded
  • NVCR 2000
  • TRMK 1889
  • Country
  • NVCR Switzerland
  • TRMK United States
  • Employees
  • NVCR N/A
  • TRMK N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TRMK Major Banks
  • Sector
  • NVCR Health Care
  • TRMK Finance
  • Exchange
  • NVCR Nasdaq
  • TRMK Nasdaq
  • Market Cap
  • NVCR 1.9B
  • TRMK 2.2B
  • IPO Year
  • NVCR 2015
  • TRMK 1987
  • Fundamental
  • Price
  • NVCR $17.60
  • TRMK $38.50
  • Analyst Decision
  • NVCR Buy
  • TRMK Buy
  • Analyst Count
  • NVCR 7
  • TRMK 4
  • Target Price
  • NVCR $32.43
  • TRMK $40.50
  • AVG Volume (30 Days)
  • NVCR 1.4M
  • TRMK 329.4K
  • Earning Date
  • NVCR 07-24-2025
  • TRMK 07-22-2025
  • Dividend Yield
  • NVCR N/A
  • TRMK 2.49%
  • EPS Growth
  • NVCR N/A
  • TRMK 50.91
  • EPS
  • NVCR N/A
  • TRMK 3.85
  • Revenue
  • NVCR $621,711,000.00
  • TRMK $544,423,000.00
  • Revenue This Year
  • NVCR $5.56
  • TRMK $57.13
  • Revenue Next Year
  • NVCR $9.19
  • TRMK $3.95
  • P/E Ratio
  • NVCR N/A
  • TRMK $10.01
  • Revenue Growth
  • NVCR 18.27
  • TRMK N/A
  • 52 Week Low
  • NVCR $14.17
  • TRMK $29.77
  • 52 Week High
  • NVCR $34.13
  • TRMK $40.73
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 49.74
  • TRMK 69.65
  • Support Level
  • NVCR $16.81
  • TRMK $35.96
  • Resistance Level
  • NVCR $18.59
  • TRMK $38.97
  • Average True Range (ATR)
  • NVCR 0.74
  • TRMK 0.91
  • MACD
  • NVCR 0.08
  • TRMK 0.24
  • Stochastic Oscillator
  • NVCR 56.18
  • TRMK 90.06

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About TRMK Trustmark Corporation

Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.

Share on Social Networks: